Trial · NCT02437136
Adverse event totals21
The totals the trial posted for each group.
1 to 20 of 21
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Phase 1b (Dose Escalation): Entinostat 3 mg Weekly + Pembrolizumab | 6 | 6 |
| Total, all-cause mortality | Phase 1b (Dose Escalation): Entinostat 5 mg Weekly + Pembrolizumab | 0 | 7 |
| Total, all-cause mortality | Phase 1b (Dose Confirmation): Entinostat 5 mg Weekly + Pembrolizumab | 1 | 9 |
| Total, all-cause mortality | Phase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab | 8 | 18 |
| Total, all-cause mortality | Phase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab | 41 | 76 |
| Total, all-cause mortality | Phase 2, Cohort 3: Entinostat 5 mg Weekly + Pembrolizumab | 31 | 53 |
| Total, all-cause mortality | Phase 2, Cohort 4: Entinostat 5 mg Weekly + Pembrolizumab | 25 | 38 |
| Total, other adverse events | Phase 1b (Dose Escalation): Entinostat 3 mg Weekly + Pembrolizumab | 6 | 6 |
| Total, other adverse events | Phase 1b (Dose Escalation): Entinostat 5 mg Weekly + Pembrolizumab | 7 | 7 |
| Total, other adverse events | Phase 1b (Dose Confirmation): Entinostat 5 mg Weekly + Pembrolizumab | 9 | 9 |
| Total, other adverse events | Phase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab | 18 | 18 |
| Total, other adverse events | Phase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab | 75 | 76 |
| Total, other adverse events | Phase 2, Cohort 3: Entinostat 5 mg Weekly + Pembrolizumab | 52 | 53 |
| Total, other adverse events | Phase 2, Cohort 4: Entinostat 5 mg Weekly + Pembrolizumab | 37 | 38 |
| Total, serious adverse events | Phase 1b (Dose Escalation): Entinostat 3 mg Weekly + Pembrolizumab | 4 | 6 |
| Total, serious adverse events | Phase 1b (Dose Escalation): Entinostat 5 mg Weekly + Pembrolizumab | 4 | 7 |
| Total, serious adverse events | Phase 1b (Dose Confirmation): Entinostat 5 mg Weekly + Pembrolizumab | 2 | 9 |
| Total, serious adverse events | Phase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab | 10 | 18 |
| Total, serious adverse events | Phase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab | 33 | 76 |
| Total, serious adverse events | Phase 2, Cohort 3: Entinostat 5 mg Weekly + Pembrolizumab | 24 | 53 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02437136/event-totals